We have previously shown that allosteric CYP46A1 activation by low-dose efavirenz in a transgenic mouse model of Alzheimer’s disease (AD) enhanced both cholesterol elimination and turnover in the brain and improved animal performance in memory tests. This evidence concerns the gene CYP46A1 and early-onset autosomal dominant Alzheimer disease.